Pancreatic cancer is among the most lethal malignancies because it is frequently diagnosed after the disease has invaded surrounding tissues or spread to distant organs. Even when surgery is possible, recurrence is common, and systemic therapy remains essential for many patients. Gemcitabine, a nucleoside analogue, has long been a central component of pancreatic cancer treatment. Once transported into cancer cells, the drug is phosphorylated into active metabolites that resemble naturally occurring nucleotides. These metabolites can become incorporated into newly synthesized DNA, interrupt DNA replication, and inhibit the production of additional deoxynucleotides required for cell division. In principle, rapidly proliferating tumor cells should be particularly vulnerable to this form of attack. In practice, pancreatic tumors often adapt through changes in drug transport, DNA repair, cell death signaling, and metabolism.

The new work focuses on VRK2, a serine/threonine protein kinase whose activity has been associated with cellular signaling, stress responses, and tumor biology. Protein kinases regulate other proteins by transferring phosphate groups to them, a modification that can alter protein stability, location, interactions, or enzymatic activity. In pancreatic cancer, the researchers found that increased VRK2 was associated with resistance to gemcitabine. Cells containing elevated VRK2 were better able to maintain their viability during treatment, whereas reducing VRK2 weakened the resistant phenotype. This relationship indicates that VRK2 is not merely a passive marker of aggressive disease but may actively contribute to the cellular changes that allow malignant cells to tolerate chemotherapy.

The pathway identified by the researchers leads from VRK2 to TPI1, an enzyme positioned at a crucial junction in glycolysis. Glycolysis breaks down glucose through a series of reactions, ultimately generating pyruvate while producing a limited amount of ATP and metabolic intermediates. TPI1 catalyzes the reversible conversion of dihydroxyacetone phosphate into glyceraldehyde-3-phosphate, ensuring that carbon entering one branch of glycolysis can continue through the energy-producing portion of the pathway. Although this reaction may appear chemically simple, it is essential for maintaining the flow of glucose-derived carbon through the pathway. Altering TPI1 abundance or activity can therefore reshape the metabolic capacity of a cancer cell.

The study connects VRK2-dependent resistance with a stronger reliance on aerobic glycolysis, a metabolic pattern commonly associated with the Warburg effect. In this state, cells consume glucose rapidly and convert much of it into lactate even when oxygen is available for mitochondrial oxidative phosphorylation. Aerobic glycolysis yields less ATP per molecule of glucose than complete mitochondrial oxidation, but it can provide cancer cells with speed and flexibility. High glycolytic flux supplies intermediates for nucleotide, amino acid, and lipid synthesis, while also supporting the redox balance required for continued growth under stress. For a cell exposed to gemcitabine, this metabolic reprogramming may help preserve the resources needed to repair damage and avoid programmed cell death.

TPI1 appears to be a key mediator of this adaptation. According to the researchers, VRK2 promotes a TPI1-driven glycolytic program, allowing pancreatic cancer cells to increase glucose utilization and sustain energy production during chemotherapy exposure. This may be especially important because gemcitabine creates a replication crisis: DNA synthesis is disrupted, nucleotide pools are disturbed, and unresolved damage can activate apoptosis. By enhancing glycolytic metabolism, resistant cells may generate ATP more rapidly, maintain biosynthetic precursors, and support stress-management systems that prevent the damaged cells from crossing the threshold into cell death. The findings therefore frame drug resistance not only as a problem of drug entry or DNA repair, but also as a consequence of how tumor cells fuel themselves.

At the molecular level, the proposed mechanism illustrates how signaling and metabolism become intertwined in cancer. VRK2 functions as an upstream regulatory factor, while TPI1 operates within the core machinery of glucose breakdown. A kinase-driven increase in glycolytic capacity could influence several downstream processes simultaneously, including the production of lactate, the balance between oxidized and reduced cofactors, and the availability of carbon skeletons for macromolecule synthesis. These changes can alter the response to chemotherapy even if the drug reaches the tumor and forms its intended molecular targets. In this model, gemcitabine resistance is not simply a genetic shield against the drug; it is a physiological state maintained by a coordinated signaling-metabolic network.

The researchers used experimental approaches to examine the relationship among VRK2, TPI1, glycolysis, and gemcitabine response in pancreatic cancer models. Their analyses support the view that manipulating VRK2 changes the metabolic behavior of tumor cells and that TPI1 is necessary for the resistance program. When the pathway is disrupted, the cells become more vulnerable to gemcitabine, linking the biochemical observations to a potentially actionable therapeutic strategy. The work also strengthens the idea that metabolic enzymes traditionally viewed as housekeeping proteins can become critical dependencies in cancer. A tumor may survive by exploiting a normal metabolic reaction, but that dependence can create a weakness if it is identified and selectively targeted.

The findings raise the possibility of combining gemcitabine with therapies directed against VRK2, TPI1, or associated glycolytic processes. Such an approach could, in theory, force resistant cancer cells away from the metabolic state that protects them during treatment. However, translating this concept into a clinical therapy will require careful evaluation. Glycolysis is essential in many normal tissues, and systemic inhibition could produce toxicity. VRK2 may also participate in signaling pathways outside the tumor, while TPI1 is required for ordinary cellular metabolism throughout the body. The most effective strategy may therefore depend on identifying tumors with unusually high VRK2 activity or a demonstrable TPI1-centered glycolytic signature, allowing treatment to be directed toward patients most likely to benefit.

The study’s broader message is that pancreatic cancer resistance may be understood more effectively when genetic signaling, metabolism, and cell-death control are considered together. A tumor cell does not respond to gemcitabine in isolation; it responds as a living system that can alter its fuel consumption, stress pathways, and biosynthetic priorities. By linking VRK2 to TPI1-driven aerobic glycolysis, the researchers provide a mechanistic explanation for how pancreatic cancer cells can remain viable under chemotherapy pressure. Further studies will need to determine how consistently this pathway operates in patient tumors, whether it predicts treatment failure, and which combinations can block it without harming healthy tissue. If validated, the VRK2–TPI1 axis could become a new target in the continuing effort to make gemcitabine more effective against one of the most treatment-resistant cancers.

Subject of Research: The role of vaccinia-related kinase 2 and TPI1-driven aerobic glycolysis in pancreatic cancer resistance to gemcitabine.

Article Title: Vaccinia-related kinase 2 confers pancreatic cancer with gemcitabine resistance through TPI1-driven aerobic glycolysis.

Article References: Zhu, H., Xu, B., Zhu, R. et al. Vaccinia-related kinase 2 confers pancreatic cancer with gemcitabine resistance through TPI1-driven aerobic glycolysis. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03303-8

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03303-8

Keywords: Pancreatic cancer, gemcitabine resistance, vaccinia-related kinase 2, VRK2, TPI1, aerobic glycolysis, cancer metabolism, Warburg effect, chemotherapy resistance.

Glucose metabolism has long been understood as a fundamental biological process, essential for the energy production required by cells. However, its direct implications in cancer biology have captured scientific attention, revealing a duality where glucose fuels cancer cells’ growth while simultaneously engaging with immune pathways. This intersection of metabolism and immunology presents unique challenges and opportunities for researchers aiming to develop precise interventions that could disrupt cancer progression.

One of the most revealing aspects of glucose metabolism in cancer is the phenomenon known as the Warburg effect, where cancer cells preferentially utilize aerobic glycolysis even in the presence of oxygen. This leads to the production of lactate, even when oxidative phosphorylation could yield more energy. It is suggested that this metabolic shift helps cancer cells thrive in a low-oxygen environment, aiding in their proliferation and survival. Understanding this mechanism is crucial, as it provides insights into potential metabolic vulnerabilities that could be targeted in therapeutic approaches.

The immune system’s interaction with cancerous cells is another layer of complexity in this research domain. Cancer cells manipulate glucose metabolism not only to fuel their own growth but also to evade the immune system. For instance, elevated lactate levels can lead to an immunosuppressive tumor microenvironment. By understanding these interactions, researchers can devise strategies to bolster immune responses against tumors while simultaneously inhibiting the cancer cells’ metabolic advantages.

Emerging strategies in targeting glucose metabolism for cancer treatment are gaining traction. By employing drugs that inhibit specific enzymes involved in glycolysis, researchers hope to starve cancer cells of their energy supply. These metabolic inhibitors could potentially be used in conjunction with immunotherapies, creating a synergistic effect that enhances anti-tumor activity while reducing harmful side effects. This dual approach represents a promising frontier in oncology, emphasizing the need for more nuanced treatment regimens that account for both metabolic and immunological factors.

Moreover, the authors highlight that personalized medicine could significantly benefit from advances in understanding glucose metabolism’s role in cancer. Different tumors may exhibit varying metabolic profiles based on their genetic make-up and microenvironment. By tailoring therapies to individual metabolic signatures, oncologists could improve treatment efficacy and patient outcomes. This level of precision represents a significant leap forward in cancer care, moving away from one-size-fits-all approaches.

In their study, the authors also explore alternative fuels that tumors may utilize when glucose is limited. Some tumors can switch to utilizing ketone bodies or fatty acids, demonstrating remarkable metabolic flexibility. This adaptability complicates treatment strategies, as targeted inhibition of glucose metabolism may inadvertently drive tumors to rely more heavily on alternative energy sources. Researchers are tasked with identifying these metabolic pathways and developing strategies to block them effectively.

Furthermore, the connection between glucose metabolism and inflammatory pathways in cancer presents another avenue for exploration. Chronic inflammation is a recognized hallmark of cancer, and it is closely linked with metabolic processes. The intersection of these pathways could offer insights into how interventions aimed at metabolic reprogramming could also exert anti-inflammatory effects, potentially reducing tumor-driven inflammation and boosting immune responses.

The research community faces diverse challenges in translating these findings into clinical practice. One key hurdle is effectively delivering metabolic inhibitors to tumor sites while minimizing impact on normal tissues. Developing targeted delivery systems and combining metabolic inhibitors with traditional chemotherapies and immunotherapies could enhance effectiveness while reducing toxicity.

Additionally, the long-term effects of manipulating glucose metabolism in cancer patients remain to be fully understood. Researchers must consider the potential for developing resistance to metabolic therapies or unanticipated side effects arising from prolonged treatment. Ongoing clinical trials and patient monitoring will be essential to elucidate the safety and efficacy of these novel approaches.

As these scientific investigations continue to unfold, the promise of metabolic targeting in cancer treatment shines brighter than ever. By unraveling the complex relationship between glucose metabolism, cancer biology, and immune regulation, researchers are not only expanding our understanding of cancer but also paving the way for innovative therapeutic interventions. The potential to combine metabolic and immunological therapies could revolutionize cancer treatment, giving hope to patients who have long battled this formidable disease.

In conclusion, the work presented by the authors underscores the urgency and importance of metabolism-centered research in the field of oncology. Their findings pose critical questions regarding the role of glucose in cancer and immunity, urging both researchers and clinicians to rethink traditional paradigms of cancer treatment. As we journey into this new era of targeted therapies, the quest to decode the intricate webs of metabolism and immunology continues to offer exciting possibilities for transforming cancer care.

Subject of Research: The role of glucose metabolism in cancer progression and immune regulation.

Article Title: Glucose metabolism and its direct action in cancer and immune regulation: opportunities and challenges for metabolic targeting.

Article References:

Pan, BS., Hsu, CC., Wu, HE. et al. Glucose metabolism and its direct action in cancer and immune regulation: opportunities and challenges for metabolic targeting.
J Biomed Sci 32, 71 (2025). https://doi.org/10.1186/s12929-025-01167-1

Image Credits: AI Generated

DOI: 10.1186/s12929-025-01167-1

Keywords: glucose metabolism, cancer, immune regulation, metabolic targeting, Warburg effect, personalized medicine, metabolic inhibitors, tumor microenvironment, chronic inflammation.